- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug treatment early after traumatic brain injury reduces epilepsy risk
In a study appearing in Annals of Neurology, researchers have found that early intervention following traumatic brain injury reduces epilepsy risk
CALIFORNIA: The development of epilepsy is a major clinical complication after brain injury and traumatic brain injury is a major risk factor for acquired epilepsies. Early intervention may identify targets of epileptogenesis after traumatic brain injury and prevent epilepsy.
A research team led by a scientist at the University of California, Riverside, has found that brains treated with certain drugs within a few days of an injury have a dramatically reduced risk of developing epilepsy later in life.
"Working on rats, whose immune response system models that of humans, we identified that after brain injury a certain immune system receptor makes the brain more excitable, which promotes development of epilepsy," said Viji Santhakumar, an associate professor of molecular, cell, and systems biology at UC Riverside and the lead author of the study that appears in the Annals of Neurology. "If this receptor can be suppressed, preferably within a day after injury, the future development of epilepsy can be reduced if not entirely prevented."
Read Also: IV magnesium sulfate improves outcomes 6 months after brain surgery
The receptor in question is the Toll-like receptor 4, or TLR4, an innate immune receptor. Following a brain injury, TLR4 increases excitability in the dentate gyrus of the hippocampus, the brain structure that plays a major role in learning and memory.
Santhakumar explained two factors are involved in brain injury: a neurological complication and the immune system. These factors have traditionally been studied separately, she said.
"Our team, however, studied these factors together," she added. "This approach helped us understand that the immune system operates through a very different mechanism in the injured brain than in the uninjured brain. Understanding the difference can guide us on how best to target treatments aimed at preventing epilepsy after traumatic brain injury."
The team specifically studied concussions, the kind suffered by many football players, which can lead to cell death in the hippocampus, affecting the processing of memory. Cell death activates the immune system, including TLR4. TLR4, in turn, increases excitability in the hippocampus.
"What our rat studies on traumatic brain injury show is that if we target early changes in excitability, we can alter long-term pathology," Santhakumar said. "Blocking TLR4 signaling shortly after brain injury reduces neuronal excitability in the hippocampus and seizure susceptibility. This seizure susceptibility is not reduced if we delay the blocking of TLR4 signaling after injury."
Read Also:Mothers on antiepileptic medications can safely breastfeed: JAMA
Paradoxically, Santhakumar's team found that drugs such as Resatorvid, which block TLR4 in the injured brain, caused epilepsy in uninjured brains.
"This paradox is difficult to understand," Santhakumar said. "We are currently looking at molecular signalling pathways in injured and uninjured brains to make sense of it."
The study could have important implications for war veterans returning home with brain injuries.
"Most often, the consequences of their injuries don't show up a year later, but several years later," said Santhakumar, who came to UCR in 2018 from Rutgers University.
The study focused only on epilepsy, one of several pathologies that can follow brain injury.
"Deficits in memory, cognition, and social behaviours could also follow brain injury," Santhakumar said. "In future work, we plan to study co-morbidities associated with traumatic brain injury."
Read Also: Daily exposure to blue light aids healing of traumatic brain injury
For further reference log on to :
Akshata A. Korgaonkar, Ying Li, Dipika Sekhar, Deepak Subramanian, Jenieve Guevarra, Bogumila Swietek, Alexandra Pallottie, Sukhwinder Singh, Kruthi Kella, Stella Elkabes, Vijayalakshmi Santhakumar. Toll‐like Receptor 4 Signaling in Neurons Enhances Calcium‐Permeable α‐Amino‐3‐Hydroxy‐5‐Methyl‐4‐Isoxazolepropionic Acid Receptor Currents and Drives Post‐Traumatic Epileptogenesis. Annals of Neurology, 2020; DOI: 10.1002/ana.25698
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751